China Universal Asset Management Co. Ltd. Purchases 727 Shares of Harrow, Inc. (NASDAQ:HROW)

China Universal Asset Management Co. Ltd. boosted its position in shares of Harrow, Inc. (NASDAQ:HROW) by 10.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,552 shares of the company’s stock after purchasing an additional 727 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Harrow were worth $253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new position in shares of Harrow in the third quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the last quarter. Hills Bank & Trust Co bought a new position in shares of Harrow in the third quarter valued at about $107,000. Huntington National Bank acquired a new position in Harrow during the 3rd quarter worth about $164,000. Finally, Clarus Group Inc. bought a new stake in Harrow during the 3rd quarter worth about $225,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Performance

Shares of HROW stock opened at $30.72 on Monday. The stock has a market cap of $1.09 billion, a PE ratio of -32.68 and a beta of 0.72. The stock has a 50-day moving average of $35.93 and a 200-day moving average of $39.62. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a one year low of $9.13 and a one year high of $59.23.

Analyst Upgrades and Downgrades

Separately, B. Riley dropped their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.